Skip to content

Romosozumab

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone formation. By blocking sclerostin, romosozumab increases bone formation and decreases bone resorption, making it a valuable treatment for osteoporosis and improving bone density, which is crucial for longevity and reducing fracture risk in aging populations.

Intelligence Profile

Safety Profile

Romosozumab is a medication used for osteoporosis treatment. Its safety profile has been evaluated in several studies and clinical trials, but evidence regarding certain aspects is still developing.

Known Side Effects

Romosozumab has been associated with the following side effects:

  • Injection site reactions
  • Joint pain
  • Headaches
  • Back pain

Contraindications

Individuals with the following conditions should generally avoid romosozumab:

  • Hypocalcemia (low calcium levels)
  • A history of myocardial infarction or stroke, as evidence suggests potential cardiovascular risks.

Cardiovascular Risk

Research indicates a heightened risk of cardiovascular events with romosozumab. According to a propensity score-matched analysis, there might be a higher incidence of cardiovascular outcomes compared to some other therapies. This is particularly noted in patients with pre-existing cardiovascular conditions.

Drug Interactions

Specific drug interactions are not extensively detailed in the evidence. Clinicians should closely monitor patients taking multiple medications for bone health.

Populations to Avoid

Besides those with contraindications, caution is advised for:

  • Patients with chronic kidney disease, as mineral dysregulation can lead to additional health concerns.
  • Patients who have suffered a recent cardiovascular event.

Evidence Gaps

While safety data from completed trials are available, ongoing studies (including phase 4 trials) suggest the need for continued research, particularly to fully understand long-term safety and comparative effectiveness with other treatments.

Disclaimer

This information is grounded in current research. For personalized advice, consult a healthcare professional.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.